Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers

Next Previous
Search
Trial Profile

A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Pegnivacogin
  • Indications Acute coronary syndromes; Venous thrombosis
  • Focus Adverse reactions
  • Sponsors Regado Biosciences

    • Most Recent Events

    • 23 Jun 2014 Data from this study were published in the Journal of Thrombosis and Thrombolysis, according to a Regado media release.
    • 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 15 Nov 2010 Results were presented at the American Heart Association (AHA) Scientific Sessions meeting, according to a Regado Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top